Windlas Biotech Shares: ‘Buy on Dips’ Until Breakout, Says SEBI Analyst

A breakout above ₹1,025 could trigger an uptrend towards ₹1,160–₹1,350, according to the analyst.

Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup. A clean breakout above ₹1,025 will confirm the next strong uptrend. Until then, it remains a “buy-on-dips” candidate, they added. 

Let’s take a look at the rationale behind their recommendation. 

Fundamental View

Windlas Biotech has demonstrated steady growth over the last two years. Sales have risen from ₹120 crore in June 2022 to ₹210 crore in June 2025, a 75% jump with continuous quarter-on-quarter growth. Its operating profit has also grown from ₹14 crore to ₹27 crore during the same period, while EPS has nearly doubled from ₹4.50 to ₹8.40. 

Margins remain stable at 12–13% OPM, and the company continues to operate on a low-debt model, which provides strength during pharma downturns as well. 

Technical View

According to Finkhoz, its price action is showing accumulation and strength. The stock has seen strong support near ₹925, its 200-day Exponential Moving Average (EMA). Immediate resistance is pegged at ₹1,025 – a level that has been tested multiple times. 

A breakout above ₹1,025 can open the gate to ₹1,160 and higher, according to them. The stock is currently trading above the 50-day EMA (₹967), indicating that the buyers are active on dips. 

Windlas Biotech is forming a Cup & Handle pattern on the chart and a breakout above ₹1,025 can open the road towards ₹1,350, they concluded.

News Triggers 

The pharma CDMO sector is gaining momentum with PLI scheme tailwinds, and Windlas is a key beneficiary. And according to Finkhoz, Windlas Biotech stands out for its consistent EPS growth and stable margins — making it a steady compounder. 

What Is The Retail Mood?

Data on Stocktwits shows that retail sentiment has remained ‘neutral.’

Windlas shares have declined 3% year-to-date (YTD).

For updates and corrections, email newsroom[at]stocktwits[dot]com.<